Tirzepatide: Safety Profile & Research Summary
12 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: May 2026
Preclinical Research Summary
Foundational Studies
| Study | Model | Key Findings | Ref |
|---|---|---|---|
| Drucker et al. (1996) | Glucagonoma xenograft mice | First identification of GLP-2 intestinotrophic activity; small-bowel hyperplasia mapped to the 33-mer proglucagon-derived peptide | [1] |
| Drucker et al. (1997) | Mouse pharmacokinetic / structure-activity | Ala²Gly substitution confers DPP-IV resistance; in-vivo half-life extended ~10× vs native GLP-2 with full agonist activity preserved | [2] |
| Munroe et al. (1999) | GLP-2R cloning and characterization | Identified the GLP-2R as a class B Gαs-coupled GPCR; characterized receptor distribution across intestinal cell populations | [5] |
| Dubé et al. (2006) | IGF-1R conditional-knockout mice | Established that the intestinotrophic response to teduglutide requires intact IGF-1R signaling on intestinal epithelial cells | [7] |
| Boushey et al. (1999) | DSS-colitis mice | Reduced histological injury scores; preserved barrier integrity; reduced enterocyte apoptosis vs vehicle | [9] |
| Burrin et al. (2005) | Neonatal piglet TPN model | GLP-2 / teduglutide preserved villus height and mucosal mass during prolonged parenteral nutrition | [10] |
| Prasad et al. (2000) | Rat mesenteric ischemia-reperfusion | Reduced apoptosis index, improved barrier-recovery kinetics post-reperfusion | [11] |
| Cheeseman & Tseng (1996) | Rat jejunal Ussing-chamber | GLP-2R activation increased apical SGLT1-mediated glucose-transport capacity independent of mucosal-mass change | [4] |
Mechanistic Themes
- DPP-IV-resistant pharmacokinetics — single Ala²Gly substitution underwrites the entire research utility of the molecule
- Indirect trophic action — GLP-2R is not on the proliferating cell; IGF-1 and KGF carry the signal from receptor-bearing fibroblasts to crypt stem cells
- Receptor selectivity — clean GLP-2R-selective probe within the proglucagon-derived peptide family
- Reproducible morphometric endpoints — villus height, crypt depth, mucosal mass, citrulline, ZO-1/occludin expression are well-validated assay readouts
In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro) and/or animal model studies. These results may not translate to human outcomes. No claims are made regarding human therapeutic applications.
Educational Use Only: This content is provided for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult qualified healthcare professionals for medical decisions.
Expert Observation
“Preclinical Research Summary Foundational Studies StudyModelKey FindingsRef Drucker et al.”
References
- Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93(15):7911-7916.
- Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15(7):673-677.
- Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275(5):G911-G921.
- Cheeseman CI, Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol. 1996;271(3):G477-G482.
- Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96(4):1569-1573.
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.
- Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605.
- Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48(11):1289-1299.
- Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277(5):E937-E947.
- Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1):22-32.
- Prasad R, Alavi K, Schwartz MZ. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg. 2000;35(2):357-359.
- Yusta B, Holland D, Koehler JA, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009;137(3):986-996.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.